Reports preliminary FY25 revenue $45.2M, consensus $44.62M. “TriSalus continued to deliver strong commercial performance in the fourth quarter and exceeded our 2025 guidance of 50% annual revenue growth, underscoring the meaningful clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications,” said Mary Szela, president and CEO of TriSalus. “We are pleased not only with our commercial execution but also with the sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver and deepening our engagement within the interventional radiology community. Looking ahead to 2026, we expect full-year revenues to be in a range of approximately $60 million to $62 million.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences named a 2026 Top Pick at Northland
- Expanding Indications and Diversified Revenue Base Support Buy Rating on TriSalus Life Sciences
- TriSalus Life Sciences price target raised to $12 from $11 at Canaccord
- TriSalus Life Sciences: Strong Growth Prospects and Strategic Developments Reinforce Buy Rating
- TriSalus Life Sciences: Strong Revenue Growth and Strategic Initiatives Drive Buy Rating